RedHill Awaits US Patent for Antibiotic Combo, RHB-104, as Potential RRMS Therapy
RedHill Biopharma has received aĀ Notice of AllowanceĀ for a new patent onĀ RHB-104Ā its potential therapy for patients with relapsing-remitting multiple sclerosis (RRMS). Once granted by the United States Patent and Trademark Office (USPTO),Ā this patent will be valid until 2032. RHB-104 is a proprietary, orally-administered antibiotic combinationĀ with potentially potent intracellular, antimycobacterial…